Purpose: The purpose of this study was to assess the results of abdominal aortic aneurysm repair with the PowerLink bifurcated endovascular graft (Endologix, Inc, Irvine, Calif). Method: Twelve centers used the PowerLink bifurcated system for elective endovascular aneurysm repair in 118 patients recruited during a 16-month interval and followed for a 25-month interval (mean follow-up, 16 months) as part of a pivotal US Food and Drug Administration trial. Stent grafts were oversized by 10% to 20% relative to computed tomographic scan-based diameter measurements. All repairs were performed in the operating room through one surgically exposed femoral artery and a contralateral 9F sheath percutaneously placed. Results were assessed with contrast-enhanced computed tomography and plain abdominal radiography at 1, 6, and 12 months after surgery. Results: Three failed insertions and one late conversion for endoleak remediation occurred, resulting in four conversions (3.3%) to open surgery. Of the failed insertions, two were from a faulty delivery system design, which was corrected. No failures occurred after the modification. One perioperative death (0.8%) occurred that was not device related. Eight late deaths were from unrelated causes, and one was from complications after reoperation for treatment of an endoleak. Endoleaks were noted in 19 patients (16%) at the time of the endograft procedure: 12 resolved spontaneously, four resolved with secondary interventions (three type I, one type II), and three underwent observation, yielding a 30-day endoleak rate of 5.9%. Two graft limb thromboses (0.8%) were seen. One graft migration (0.8%) was of no clinical significance. No ruptures or wire fractures were found. The mean aneurysm diameter was reduced from 51 mm (preoperative) to 45 mm (12 months; P < .0001). Conclusion: The PowerLink system appears to be safe and effectively protects patients from abdominal aortic aneurysm rupture over the short to medium term. The low endoleak rate is superior to that reported for other devices. The graft and stent materials have thus far been free from failure and fatigue. The sutureless stent and endoskeleton design confer a number of unique advantages and challenges. Careful follow-up over the longer term is necessary to assure the durability of these results. (J Vasc Surg 2002;36:1129-37.)
Since the initial report of endovascular aneurysm repair by Parodi, Palmaz, and Barone 1 in 1991, a number of endovascular stent graft strategies and devices have been developed. Earlier experience with other first generation endovascular aortic aneurysm repair (EVAR) devices prompted the development of a new device that could retain the successful features of these earlier designs but address their shortcomings with the introduction of novel features. A unibody, bifurcated, fully supported EVAR graft with a simple deployment scheme was created. We report the results of a prospective, multicenter clinical trial with the PowerLink bifurcated system (Endologix, Inc, Irvine, Calif) for repair of nonruptured infrarenal abdominal aortic aneurysms (AAAs).
METHODS

Trial design.
A trial of the safety and efficacy of the Endologix PowerLink bifurcated system was conducted at 12 centers (Appendix) according to US Food and Drug Administration guidelines. This device has been used in Europe since 1999 and has been under an Investigational Device Exemption in the United States in the context of a pivotal Food and Drug Administration trial. Each center obtained approval from its Institutional Review Board for Human Subject Investigations, and informed consent was obtained from all patients. The device is shown in Fig 1. The PowerLink bifurcated system is a self-expanding, fully stented endovascular graft. The stented endoskeleton is constructed as a single-wire body with a double spine, without sutures or welds. The stented portion is constructed from a nonnitinol, stainless steel metal alloy with high chromium content (conichrome). The endoskeleton is covered with graft material made from expanded polytetrafluoroethylene (ePTFE). The design is one-piece bifurcated. The graft material is sutured to the endoskeleton only at the ends of the device. The device is supplied in two neck diameters (25 mm and 28 mm) and two lengths (135 mm and 155 mm). The limbs of the bifurcated stent graft are 16 mm in diameter. The delivery sheath has a 21F outer diameter and a long tapered tip. Both proximal and distal extension cuffs are available. Fig 2 shows the device insertion procedure.
The device was delivered through one surgically exposed femoral artery and one percutateously accessed femoral artery. A peel-away 12.5F sheath was placed under direct vision into the surgically exposed ipsilateral femoral artery, and a 9F sheath was placed percutaneously into the contralateral femoral artery. Transfemoral wire access then was established across the aortic bifurcation (Fig 2, A) . Over the transfemoral wire, a dual-lumen catheter was placed across the aortic bifurcation, exiting both femoral artery sheaths (Fig 2, B) . Through the central lumen of this catheter, the contralateral limb wire of the device was introduced from the femoral cut down side exiting the percutaneously placed contralateral sheath. Through the outer lumen of this dual-lumen catheter, the wire over which the device was to be introduced into the aorta was placed. This wire exited a side hole in the dual lumen catheter, positioned in the proximal, ipsilateral common iliac artery, allowing the wire to be guided through the aneurysm sac and neck into the thoracic aorta. The patient then underwent anticoagulation with heparin. The duallumen catheter then was removed, leaving the contralateral limb wire and device delivery wires in place with assurance of their separation and freedom from wrapping (Fig 2, C) . The peel-away sheath then was removed, and the device's tapered tip was inserted via the wire into the arterial puncture. The device was fluoroscopically guided into the proximal abdominal aorta, and an arteriogram was performed via an angiographic catheter placed through the 9F contralateral sheath (Fig 2, D) . The locations of the aortic bifurcation and renal arteries were noted. Manipulation of the components of the delivery sheath allowed deployment of the graft in stages: first, the contralateral limb was unsheathed to free it from the ipsilateral limb, without deploying either limb (Fig 2, E) ; the device was brought caudad to bring the iliac limbs and main body into position; the main body then was partially deployed (Fig 2, F) ; the contralateral limb then was fully deployed with application of traction to the contralateral limb wire, pulling a covering "cap" off of the self-expanding limb (Fig 2, G) ; this cap and attached contralateral limb wire then were withdrawn through the 9F contralateral sheath; final positioning of the main body proximal attachment was confirmed and the main body was fully deployed (Fig 2, H) ; and finally, the ipsilateral iliac limb was deployed with retraction of its covering sheath and the delivery system was retrieved with withdrawal of the delivery system through the main body of the endograft (Fig 2, I) . An arteriogram was performed at the completion of the procedure. If necessary, proximal or distal extension cuffs were placed. Balloon dilatation of attachment points was performed only if deemed necessary after completion arteriography. After surgical closure of the ipsilateral arteriotomy, the heparin was reversed with administration of protamine sulfate. The contralateral 9F PowerLink bifurcated system. Device is unibody, bifurcated, self-expanding, fully stented endovascular graft (A). Stented endoskeleton is constructed as single-wire body with double spine, without sutures or welds. Stented portion is constructed from nonnitinol metal alloy. Endoskeleton is covered with graft material made from ePTFE. Graft material is sutured to endoskeleton only at ends of device, allowing fabric to balloon off of endoskeleton (B). Device is supplied in two neck diameters (25 mm and 28 mm) and two lengths (135 mm and 155 mm). Limbs of bifurcated stent graft are 16 mm in diameter. Delivery sheath has 21F outer diameter and long tapered tip. Both proximal (with or without suprarenal fixation wires) and distal extension cuffs are available.
sheath was withdrawn, and puncture site hemostasis was achieved.
Patient selection. Only patients with nonruptured infrarenal aortoiliac aneurysms who were candidates for conventional open AAA repair were enrolled. Patients could not be pregnant, had to be without bleeding or connective tissue disorders, and had to be willing to comply with the follow-up schedule, with a life expectancy of more than 2 years and a serum creatinine level of 1.7 mg/dL or less. Anatomic inclusion criteria included an AAA diameter of 4.0 cm or more or a rapidly growing AAA, a proximal aneurysm neck 15 mm or more in length, a less than 60-degree angle, an 18 to 26 mm diameter, an iliac diameter of 7 mm or more on at least one side, a dispensable inferior mesenteric artery, the preservation of at least one hypogastric artery, an iliac seal zone of 1.5 cm or more, and an aortic bifurcation diameter of 18 mm or more. Patient anatomic and demographic inclusion-exclusion criteria are listed in Table I (online only). The anatomic suitability for endografting was determined with computed tomographic (CT) angiography with three-dimensional reconstruction by the central core laboratory (Medical Media Services, Lebanon, NH). Routine preoperative catheter angiography was not used.
Device selection. Preoperative measurements of aneurysm neck diameter and distance from the lowest renal artery to the aortic bifurcation and hypogastric arteries were used to determine the appropriate diameter and length of endograft. Graft diameter was determined with oversizing of the graft by 10% to 20% in excess of the measured neck diameter. Graft length was chosen so as not to cover more than one (and preferably neither) hypogastric artery.
Follow-up evaluation. Patients underwent baseline abdominal plain radiography at the time of device implantation and before hospital discharge. In addition to physical examination, abdominal four-view radiography (anteroposterior, lateral, and both left and right anterior oblique views) and CT angiography were performed at 1, 6, and 12 months after surgery. These studies were used to assess the integrity of the endograft and the aneurysm repair (migration, wire fractures, endoleak, aneurysm size). These studies were evaluated by each local site and independently by the central core laboratory (Medical Media Services).
RESULTS
Patients and procedures.
During a 16-month interval, endovascular repair of AAAs was successfully performed in 115 of 118 patients (97.5%) with the Endologix graft. Patient demographics are shown in Table II (online only). The 110 male (93%) and eight female (7%) patients had a mean age of 73 years (range, 55 to 86 years). Comorbid conditions included coronary artery disease in 54 patients (46%), congestive heart failure in five patients (4%), valvular heart disease with prior valve replacement in five patients (4%), arrhythmias in 17 patients (15%), pulmonary disease requiring medication in 36 patients (31%), diabetes mellitus in 16 patients (14%), prior stroke in nine patients (8%), history of transient ischemic attacks in six patients (5%), cigarette abuse in 91 patients (77%), hypertension in 67 patients (57%), and peripheral vascular occlusive disease in 18 patients (15%). The core laboratory noted significant calcification of the aneurysm neck in 24 patients (21%) and of the iliac arteries in 107 patients (91%), and severe iliac tortuosity in 39 patients (33%). Follow-up ranged from 10 to 25 months, with a mean follow-up interval of 16 months. No patients were lost to follow-up.
The devices used are listed in Table III (online only) . The main body devices deployed included grafts of 28 mm ϫ 135 mm (n ϭ 22; 19%), 28 mm ϫ 155 mm (n ϭ 54; 46%), 25 mm ϫ 135 mm (n ϭ 12; 10%), and 25 mm x 155 mm (n ϭ 30; 26%). Proximal cuffs were required in 64 patients (54%; all 28 mm) and distal extensions (16 mm) in 20 patients (17%).
Details of the operative procedure are shown in Table  IV (online only). Three failed insertions occurred. Of these, two were from a fault in the delivery system whereby the ipsilateral limb could not be deployed, necessitating open conversion. No occurrences of this complication were observed after a modification of the catheter design and delivery process. The remaining conversion was from premature deployment of the ipsilateral limb before positioning within the iliac artery, felt to be the result of user inexperience.
Operating room time was an average of 137 minutes (range, 49 to 345 minutes), fluoroscopy time was 23 minutes (range, 9 to 89 minutes), mean contrast usage was 195 mL (range, 40 to 420 mL), and mean estimated blood loss was 377 mL (range, 50 to 5000 mL). General anesthesia was used for 89 patients (75%), regional for six patients (5%), and local for 23 patients (20%). The mean length of stay after EVAR was 2.9 days (range, 1 to 15 days).
Mortality. Ten deaths (one perioperative and nine late) were seen in the follow-up interval. The single perioperative death (0.8%) was from fatal cardiac arrhythmia from an unknown cause, which was believed not to be device related. Of the late deaths, one was the result of multisystem organ failure after an open procedure to repair a refractory type I endoleak 1 year after EVAR. Placement of a proximal extension cuff for this patient failed to remedy the leak. The cuff then was balloon dilated, resulting in extravasation of contrast shwoing juxtarenal aortic disruption, necessitating emergent open conversion. The eight remaining late deaths were from cancer (n ϭ 4), ischemic heart disease (n ϭ 1), complications of thoracic surgery (n ϭ 1), stroke (n ϭ 1), and pneumonia complicating chronic obstructive pulmonary disease (n ϭ 1).
Complications and secondary procedures. No aneurysm ruptures or wire fractures occurred. Medical complications are listed in Table V (online only) . Other perioperative complications (within 30 days) included myocardial infarction (n ϭ 1; 0.8%), rise in serum creatinine level to more than 1.7 mg/dL (n ϭ 1; 0.8%), renal failure requiring dialysis (n ϭ 1; 0.8%), wound hematoma (n ϭ 12; 10%), wound infection (n ϭ 1; 0.8%), new onset claudication (n ϭ 3; 2.5%), hemorrhage (n ϭ 1; 0.8%), clinically insig- nificant iliac artery dissection (n ϭ 1; 0.8%), blue toes (n ϭ 1; 0.8%), and femoral pseudoaneurysm (n ϭ 1; 0.8%).
Endoleaks were noted in 19 patients (16%) at the time of the completion arteriogram at the conclusion of the operative procedure. Of these, 12 resolved spontaneously by the time of the first CT scan at 30 days, yielding a 30-day endoleak rate of 5.9%. Of the seven endoleaks remaining at 30 days, four were treated with secondary interventions. Three type I leaks were treated with extension cuffs or placement of additional stents. A type II leak was treated with translumbar coil embolization. Three type II leaks underwent observation with stable aneurysm sizes.
Two graft limb thromboses (0.8%) were seen. Both occurred at 1 month after surgery. One was treated with surgical thrombectomy, followed by angioplasty of the graft limb, and the other was treated percutaneously with thrombolytic therapy and graft limb angioplasty. One symptomatic graft limb stenosis (claudication) was noted at 15 months of follow-up. This was treated successfully with balloon angioplasty without the need for additional stent placement.
A single case (0.8%) of caudal migration of a graft was noted. This graft was located 2.1 cm below the renal arteries at 6 months, ay 2.2 cm at 9 months, and at 2.4 cm at 12 months. No endoleak was associated with the migration.
A single additional secondary procedure was required at 2 months after surgery for a patient with new onset of hip and buttock claudication. The patient was found to have a stenotic native iliac artery, which was treated with angioplasty and stent placement with good relief of symptoms.
Aneurysm diameter before and after EVAR. The preoperative mean AAA diameter was 51 mm (range, 40 to 74 mm). At 6 months, the mean AAA diameter for this cohort was 48 mm (P Ͻ .0001), and at 12 months, was 45 mm (P Ͻ .0001).
DISCUSSION
We conducted a multicenter trial of the Endologix PowerLink unibody bifurcated device in 118 patients over a 25-month follow-up interval (mean follow-up, 16 months). We found the PowerLink device to be safe, with no device-related perioperative deaths. Reduction in mean aneurysm diameter was noted over the follow-up interval. Few serious complications occurred, and the secondary procedures used to treat them were performed with minimally invasive means in most cases.
Three acute surgical conversions (2.6%) were seen, two of which were the result of a catheter limitation and unnecessary step in the delivery process, subsequently remedied, and one that resulted from premature limb deployment, which was attributed to user inexperience. One late conversion was necessary to treat a refractory type I endoleak. No device-related reason could be identified at the time of explantation to account for the inability to achieve an adequate proximal seal.
Graft limb thrombosis was uncommon (0.8%) and was treatable with surgical thrombectomy or thrombolytic therapy with angioplasty. The early timing of these events probably reflects an underlying iliac occlusive disease lesion (rather than graft conformational change introducing a kink), which was not appreciated at the time of graft insertion. Liberal use of predilatation of known iliac lesions is recommended. The fully stented body design provides support for the endograft limbs, offering protection from kinking and thrombosis over time as the aneurysm sac shrinks. These problems have plagued unsupported graft designs. 2 The presence of an endoskeleton makes thrombolytic therapy more attractive than surgical thrombectomy as a remedial strategy for limb thrombosis to avoid entrapping a thrombectomy catheter in the endoskeleton with the attendant risk of dislodging of the endograft.
The PowerLink device itself has a design that is unique among EVAR devices. It is a unibody bifurcated graft that obviates the risk of late endoleak from component separations (type III), as reported with modular bifurcated graft designs. 3 The body of the device is delivered through a single surgically exposed artery with a minimum access route diameter of 7 mm. The contralateral access is percutaneous (9F), allowing its use in a small or diseased iliac system. The main body deployment is performed in two stages, allowing for maximal stability and accuracy. We had no instances of inadvertent branch vessel occlusion. Modular extensions, both proximal and distal, including those with suprarenal fixation wires, are available. Proximal extensions were used in 54% of cases. Some investigators chose to seat the device on the aortic bifurcation and build the body of the graft cephalad to an immediately infrarenal position with placement of proximal cuffs. Other cuffs were placed for the treatment of or prophylaxis against type I proximal attachment leaks at the time of graft insertion.
Graft oversizing has recently been shown through the Eurostar registry to be important in the avoidance of type I leak. 4 The fabric covering of the PowerLink is ePTFE, which is supple, allowing the material to conform to a wide range of sizes. This attribute of the graft material and the self-expanding nature of the device allow most patients to be treated with a small inventory of grafts (two diameters and two lengths). Larger diameters are anticipated in the near future. The ePTFE appears to be durable, as no material related leaks have been observed thus far.
Another unique feature of the PowerLink is that the graft is attached to the endoskeleton only at the ends. The remainder of the body of the graft is sutureless. This allows easy intraoperative assessment of the endoleak status because there is no "blush endoleak" phenomenon, common among other grafts, produced by the passage of contrast through the fabric or suture holes in the graft body. This latter phenomenon can make it difficult to distinguish a benign transfabric leak from an attachment leak that needs further operative attention. The minimal number of sutures and nonporous ePTFE covering of the PowerLink obviate this confusion.
The endoskeleton body design of the PowerLink allows the fabric of the graft to "balloon" off of the endoskeleton, giving a distinctive and characteristic appearance (Fig 3) to the intraoperative completion angiogram and postoperative CT scans. Because this feature gives a radiographic appearance of contrast outside the graft skeleton, evaluation of the dynamic, time-resolved appearance of contrast is important when evaluating patients for the presence of endoleaks. This ballooning of the graft material off of the long endograft body allows the fabric to more completely fill the sac of the aneurysm, which may directly seal the lumbar and inferior mesenteric branch vessel ostia. This could be in whole or in part responsible for the low rate of type II endoleak seen with this device (5.8% at 30 days), compared with other graft types. 3, [5] [6] [7] [8] The absence of suture holes in the fabric also may contribute to the low endoleak rate. This low endoleak rate is among the chief advantages of this graft system.
The endoskeleton body design may also confer other benefits. We saw no instances of stent wire fracture, a problem that has plagued a number of other devices. The endoskeleton is composed of a single wire in the form of a double spine, with no welds or seams. Because the metal is not attached to the fabric except at the attachment ends, it may be less susceptible to the forces transmitted by repetitive oscillations of the fabric with the cardiac cycle. This possibly prevents fatigue in the metal, leading to greater longevity of the endoskeleton. The absence of attachment of the fabric to the entirety of the endoskeleton may also reduce the possibility of long-term fabric erosion at attachment points, a phenomenon noted with other grafts.
The endoskeleton, with its single-wire construction and long body design provides great columnar support to the endograft. This may explain the low number of observed migrations of the device (one instance), despite conformational changes after aneurysm exclusion. As noted previously, some investigators have chosen to seat the graft on the aortic bifurcation and build it cephalad to take advantage of this feature.
The endoskeleton does present special challenges to the performance of remedial procedures. The large size of stent interstices and the absence of adherent graft fabric increase the risk of weaving in and out of the endoskeleton during rewiring of the graft limbs (Fig 1, B) . Careful technique and performance of maneuvers to assure a "true lumen" course are essential. Use of J-tipped wires to rewire the graft or traversing the graft endoskeleton with a curvetipped catheter or balloon catheter have proved to be successful methods.
Importantly, no aneurysm ruptures were seen and a documented decrease in mean aneurysm size was found over the follow-up interval, suggesting efficacy in protection of patients from rupture. Also absent from our list of complications were significant iliac artery injuries, such as have been reported for other EVAR devices. 9,10 This was achieved despite a significant proportion of patients with calcified and tortuous iliac anatomy, attesting to the flexibility and tapered low-profile design of the delivery system.
CONCLUSION
The PowerLink system appears to be safe and effectively protects patients from AAA rupture over the short to medium term. The low endoleak rate appears to be superior to that reported for other devices. The graft and stent materials have thus far been free from failure and fatigue. The low profile of the delivery system and percutaneous contralateral limb access facilitate graft placement in patients with disadvantaged access routes. The sutureless stent and endoskeleton design confer a number of unique advantages and challenges. Careful follow-up over the longer term is necessary to assure the durability of these results. Additional material for this article may be found online at www.mosby.com/jvs. DISCUSSION Dr Michel S. Makaroun (Pittsburgh, Pa). Dr Brener, thank you for your kind invitation to discuss this interesting sneak preview of the multicenter trial of a new endovascular AAA device that was just presented by Dr Carpenter on behalf of the Endologix investigators. Jeff, thank you for a very clear presentation and for providing me with the manuscript for review.
I would like to congratulate the authors for some excellent early results with the new PowerLink system. The early perioperative data as well as a very enviable rate of endoleaks are certainly very promising. These are probably the result of an experienced group of investigators, in addition to the characteristics of an innovative device design.
To fill the time of the discussion, I have a few comments and questions for Dr Carpenter that I hope he will take the time to answer.
1. This is obviously a very early release of part of the trial data with very short follow-up of 7 months and without the comparable control group. In this light, are comments about rupture, wire fractures, or migrations appropriate at this stage? Most of these complications have been noted much later during follow-up with other devices. Certainly with a AAA mean size of 5.1 and an enrollment of aneurysms as small as 4 cm, one would not expect any ruptures during this limited follow-up period.
With a relatively low-profile system, such as this PowerLink,
which is 21F on the ipsilateral side, I was kind of surprised to see that female enrollment was only 7%. This is comparable if not actually less than some much larger profile devices. Do you have any good explanation for this? 3. Ninety-one percent of the iliac arteries in your series are reported to be calcified. This is unusually high. How much calcification had to be there in the iliacs to be classified as calcified? 4. There was a very high use of proximal extension cuffs with this endograft in more than half of the patients. This is more than twice as high as in any other multicenter pivotal trial. This obviously leads to a lot of speculation about the reasons. Was it because of an inaccurate proximal deployment system or because of the lack of secure fixation to the aorta? Was it due in any way to intraoperative distal migration or movement after deployment? Or was it due to a desire to have the graft bifurcation sitting on the aortic bifurcation? 5. You mentioned that the separation of the graft covering the endoskeleton partially filling the AAA sac is a desirable feature that may lead to the low rates of type II endoleaks. This is quite interesting; however, it also spurs many questions. Is this separation a major disadvantage during subsequent instrumentation? Does the graft also separate in the more than half of the patients with a proximal cuff that is usually quite long and obviously creates a screen against the main endoskeleton from the inside? Does this actually lead to a double cavity that may encourage thrombus formation and embolizations? Dr Geoffrey White reported a similarly low type II endoleak rate with a Lifepath endograft without the sac-filling mechanism that you described. Do you have any other plausible explanation for this remarkably low type II endoleak rate that up to now was always assumed to be graft independent? 6. In the absence of duplex ultrasound evaluation during followup, which has been reported by many authors to identify twice as many type II endoleaks as CT alone, can we be certain that all type II endoleaks have actually been identified? 7. Is the endoskeleton MRA compatible? 8. And finally, the limb thromboses at 1 month are a little unusual in a fully supported graft. Posttreatment aneurysm remodeling is certainly not in evidence that early. Do you have any other explanations for this early phenomenon?
Jeff, I certainly enjoyed your presentation and reading your manuscript. I again congratulate you on excellent early results in this trial. I look forward to future updates. I would finally like to thank the Society for the privilege of discussing this excellent paper.
Dr Jeffrey P. Carpenter. Mak, thank you for that careful review. I counted eight questions. Let me try to take them one by one.
I would be the first to agree with you that it is too early to reach firm conclusions about the status of this device. I am not here to be an evangelist for it. Careful follow-up is planned and necessary.
I do not have an answer for your question regarding why only 7% of our patients were women, especially with a low-profile design. Aortic aneurysm disease is a six-to-one, male-to-female, disease. But this does represent a deviation from that. I do not know if that is a statistically significant deviation or not, I have not done the math.
With respect to your question about how the device performs with calcified iliac vessels, perhaps the more important CAT scan view to review when evaluating a patient for an endovascular aneurysm repair is not the enhanced CAT scan but the unenhanced CAT scan. And as you well know, calcification can be a very challenging problem for any endovascular graft. This device is only 9F on the contralateral side, so you can treat a tortuous or calcified contralateral iliac with it nicely. One thing that we have learned over the course of the trial is to make very liberal use of preimplantation balloon angioplasty. If it even enters your mind that a lesion could be trouble, it is easiest to deal with ahead of time and predilate, much more so than we have done with other grafts. But that said, we found this graft to be very robust for small, tortuous, and even calcified iliac systems. The delivery system is nicely tapered and quite flexible.
We have offered as an explanation for the low type II endoleak rate the principle that the fabric, the skin of the graft, is able to balloon out off of the device and fill the sac. We have noted and presented data on this device and the Cook device, both of which have this long body design, and found that, at least in our hands, they have the lowest endoleak rates. The body design seems to us to be the common denominator. Whether that is really the case, I think only time will tell.
You asked whether our cuffs can seal given the endoskeleton design. We had a very high rate of cuff placement. And as you alluded to, there were a number of different reasons why these would be placed. The Europeans like to place the device on the aortic bifurcation and build up from there to guard against device migration. Some of our investigators chose to put the devices in that way. Occasionally, on withdrawal of the delivery system, since there is an endoskeleton in the graft, the block that comes down as you are pulling the device out can catch a stent strut and dislodge the device caudad. The material that is in contact with the aortic wall is PTFE, so it is quite slippery and it can come down. That is one of the drawbacks to be counterbalanced with the advantages of the endoskeleton system. Putting a cuff in is not difficult. There are no reports of patients having trouble making a seal with the proximal cuff.
Have we identified every type II endoleak? Well, Noel Parent and the MCV group in last month's Journal wrote a very provocative paper that has made all of us wonder whether we are really detecting all the endoleaks. They proposed that in their hands duplex is more sensitive than CAT scan. Many of us, in thinking about endotension, suspect that patients with stable or growing aneurysms but no detectable endoleak on CAT scan may, in fact, have occult type II endoleaks. I am confident that we have not yet devised the most sensitive test for detection of endoleak. That is a legitimate concern affecting all devices. CAT scan was the protocol's reference standard for detection of endoleak in this trial, as it has been for all other trials.
It is MR compatible. With the 2D time-of-flight MRA you cannot see anything because of stent artifact; with the addition of gadolinium, you will get a good view.
Regarding the two limb thromboses, it represents a less than 1% limb thrombosis rate, which is as good or better than all other devices. The usual mechanisms that are implicated are sac shrinkage leading to changing conformations of the aneurysm; however, ours were both detected at 1 month. It is hard to imagine that conformational change was the issue so soon after the repair, and I suspect that there was a kink or an underlying iliac lesion that should have been balloon dilated either before or after the procedure.
Dr Bruce J. Brener (Millburn, NJ). All these grafts seem to have their own intrinsic characteristics, and it seems clear from your presentation that in this one the use of a proximal cuff is frequently necessary. Investigators have expressed concern about the fact that there is considerable micromotion. And there have been some unpublished bench-type tests that show that the grafts do wear when you put a secondary device at the proximal end. In fact, one of the companies makes their proximal cuff with two separate layers of Dacron. Are you concerned, because of the large number of proximal cuffs, that you will eventually have some wear at that point? Dr Carpenter. Time will tell whether or not material fatigue becomes an issue. So far, we have not seen problems here or in Europe. A metallurgist friend of mine mentioned to me, when I described using the cuff from one device to fix the body of another device, "Aren't you worried about the electric potential difference between these, that you'll have an oxidation reduction reaction going on?" It had never occurred to me that that was something to think about. So, there are many, many issues.
Dr Brener. Should the company manufacture a cuff with suprarenal fixation to aid with a difficult neck or with a low placement?
One other question I had is this issue of precise placement. One of the dramatic aspects of this graft is the fact that it opens from the bottom up and you were using roadmapping techniques. Most grafts are placed with little puffs of contrast in order to land just below the renal arteries. How do you judge where the graft will land proximally? Do you require a long neck so that precise placement is not necessary? Dr Carpenter. The next iteration of this device-and I have only placed one of these so far-is the same device with a suprarenal fixation scheme. The anecdotal reports from other investigators who have a larger experience than my own is that they have not had to place any cuffs, that the device does not come down at all when the delivery system is withdrawn with the suprarenal fixation scheme. Operating time (min) 137 (range, 49-345) Fluoroscopy time (min) 23 (range, 9-89) Contrast (mL) 195 (range, 40-420) Regional anesthesia 6 (5%) General anesthesia 88 (75%) Local anesthesia 23 (20%) Estimated blood loss (mL) 377 (range, 50-5000) 
